<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33625943</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.</ArticleTitle>
        <Pagination>
          <StartPage>1873056</StartPage>
          <MedlinePgn>1873056</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1873056</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1873056</ELocationID>
        <Abstract>
          <AbstractText>Dendritic cell (DC) vaccines are a safe and effective means of inducing tumor immune responses, however, a better understanding of DC biology is required in order to realize their full potential. Recent advances in DC biology have identified a crucial role for cDC1 in tumor immune responses, making this DC subset an attractive vaccine target. Human cDC1 exclusively express the C-type-lectin-like receptor, CLEC9A (DNGR-1) that plays an important role in cross-presentation, the process by which effective CD8<sup>+</sup> T cell responses are generated. CLEC9A antibodies deliver antigen specifically to cDC1 for the induction of humoral, CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses and are therefore promising candidates to develop as vaccines for infectious diseases and cancer. The development of human CLEC9A antibodies now facilitates their application as vaccines for cancer immunotherapy. Here we discuss the recent advances in CLEC9A targeting antibodies as vaccines for cancer and their translation to the clinic.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lahoud</LastName>
            <ForeName>M H</ForeName>
            <Initials>MH</Initials>
            <Identifier Source="ORCID">0000-0001-8472-6201</Identifier>
            <AffiliationInfo>
              <Affiliation>Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Radford</LastName>
            <ForeName>K J</ForeName>
            <Initials>KJ</Initials>
            <Identifier Source="ORCID">0000-0001-6512-6323</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Immunotherapies Laboratory, Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C530206">CLEC9a protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037181">Lectins, C-Type</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011975">Receptors, Mitogen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019496" MajorTopicYN="Y">Cancer Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045142" MajorTopicYN="N">Cross-Priming</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037181" MajorTopicYN="Y">Lectins, C-Type</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011975" MajorTopicYN="Y">Receptors, Mitogen</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Dendritic cells</Keyword>
        <Keyword MajorTopicYN="Y">cDC1</Keyword>
        <Keyword MajorTopicYN="Y">cancer immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">clec9a</Keyword>
        <Keyword MajorTopicYN="Y">vaccines</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>17</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33625943</ArticleId>
        <ArticleId IdType="pmc">PMC8920153</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.1873056</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lee YS, Radford KJ.. 
The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019;348:123–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31810552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-019-0210-z</ArticleId>
            <ArticleId IdType="pubmed">31467405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Keeffe M, Mok WH, Radford KJ. Human dendritic cell subsets and function in health and disease. Cell Mol Life Sci. 2015;72(22):4309–25. doi:10.1007/s00018-015-2005-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-015-2005-0</ArticleId>
            <ArticleId IdType="pubmed">26243730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–52. doi:10.1016/j.ccell.2014.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2014.09.007</ArticleId>
            <ArticleId IdType="pmc">PMC4254577</ArticleId>
            <ArticleId IdType="pubmed">25446897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017. 
e4;31(5):711–23. doi:10.1016/j.ccell.2017.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC5650691</ArticleId>
            <ArticleId IdType="pubmed">28486109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat Med. 2018;24(8):1178–91. doi:10.1038/s41591-018-0085-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0085-8</ArticleId>
            <ArticleId IdType="pmc">PMC6475503</ArticleId>
            <ArticleId IdType="pubmed">29942093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, E Sousa CR. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–1037 e14. doi:10.1016/j.cell.2018.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC5847168</ArticleId>
            <ArticleId IdType="pubmed">29429633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer. 2019;7(1):109. doi:10.1186/s40425-019-0580-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0580-6</ArticleId>
            <ArticleId IdType="pmc">PMC6471787</ArticleId>
            <ArticleId IdType="pubmed">30999964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 2017;38(8):577–93. doi:10.1016/j.it.2017.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2017.05.006</ArticleId>
            <ArticleId IdType="pubmed">28610825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balan S, Arnold-Schrauf C, Abbas A, Couespel N, Savoret J, Imperatore F, Villani A-C, Vu Manh T-P, Bhardwaj N, Dalod M. Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity. Cell Rep. 2018. 
e6;24(7):1902–15. doi:10.1016/j.celrep.2018.07.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.07.033</ArticleId>
            <ArticleId IdType="pmc">PMC6113934</ArticleId>
            <ArticleId IdType="pubmed">30110645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirkling ME, Cytlak U, Lau CM, Lewis KL, Resteu A, Khodadadi-Jamayran A, Siebel CW, Salmon H, Merad M, Tsirigos A, et al. Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells. Cell Rep. 2018;23(12):3658–72. e6. doi:10.1016/j.celrep.2018.05.068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.05.068</ArticleId>
            <ArticleId IdType="pmc">PMC6063084</ArticleId>
            <ArticleId IdType="pubmed">29925006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6(232):232ra51. doi:10.1126/scitranslmed.3008068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3008068</ArticleId>
            <ArticleId IdType="pmc">PMC6151129</ArticleId>
            <ArticleId IdType="pubmed">24739759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, et al. NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin Cancer Res. 2018;24(5):1019–29. doi:10.1158/1078-0432.CCR-17-1792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-1792</ArticleId>
            <ArticleId IdType="pmc">PMC5844797</ArticleId>
            <ArticleId IdType="pubmed">28947565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhardwaj N, Friedlander PA, Pavlick AC, Ernstoff M, Gastman BR, Hanks BA, Curti BD, Albertini MR, Luke JJ, Blazquez AB, et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nature Cancer. 2020;1(12):1204–17. doi:10.1038/s43018-020-00143-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-00143-y</ArticleId>
            <ArticleId IdType="pubmed">35121932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, Lo JC, Rizzitelli A, Wu L, Vremec D, van Dommelen SL, et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood. 2008;112(8):3264–73. doi:10.1182/blood-2008-05-155176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-05-155176</ArticleId>
            <ArticleId IdType="pmc">PMC2569177</ArticleId>
            <ArticleId IdType="pubmed">18669894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis E Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008;118(6):2098–110. doi:10.1172/JCI34584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI34584</ArticleId>
            <ArticleId IdType="pmc">PMC2391066</ArticleId>
            <ArticleId IdType="pubmed">18497879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3 + dendritic cells and a subset of monocytes. J Biol Chem. 2008;283(24):16693–701. doi:10.1074/jbc.M709923200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M709923200</ArticleId>
            <ArticleId IdType="pmc">PMC2562446</ArticleId>
            <ArticleId IdType="pubmed">18408006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J-G, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, Tullett KM, Robin AY, Brammananth R, van Delft MF, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36(4):646–57. doi:10.1016/j.immuni.2012.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2012.03.009</ArticleId>
            <ArticleId IdType="pubmed">22483802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, Rosewell I, E Sousa CRE. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458(7240):899–903. doi:10.1038/nature07750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07750</ArticleId>
            <ArticleId IdType="pmc">PMC2671489</ArticleId>
            <ArticleId IdType="pubmed">19219027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, Fletcher G, Durkin C, Postigo A, Skehel M, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36(4):635–45. doi:10.1016/j.immuni.2012.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2012.03.008</ArticleId>
            <ArticleId IdType="pubmed">22483800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulz O, Hanc P, Bottcher JP, Hoogeboom R, Diebold SS, Tolar P, Reis ESC. Myosin II synergizes with F-actin to promote DNGR-1-dependent cross-presentation of dead cell-associated antigens. Cell Rep. 2018;24(2):419–28. doi:10.1016/j.celrep.2018.06.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.06.038</ArticleId>
            <ArticleId IdType="pmc">PMC6057488</ArticleId>
            <ArticleId IdType="pubmed">29996102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelenay S, Keller AM, Whitney PG, Schraml BU, Deddouche S, Rogers NC, Schulz O, Sancho D, E Sousa CR. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest. 2012;122(5):1615–27. doi:10.1172/JCI60644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI60644</ArticleId>
            <ArticleId IdType="pmc">PMC3336984</ArticleId>
            <ArticleId IdType="pubmed">22505458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahoud MH, Ahmet F, Kitsoulis S, Wan SS, Vremec D, Lee C-N, Phipson B, Shi W, Smyth GK, Lew AM, et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol. 2011;187(2):842–50. doi:10.4049/jimmunol.1101176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1101176</ArticleId>
            <ArticleId IdType="pubmed">21677141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De Rose R, Salazar AM, E Sousa CR, Shortman K, Lahoud MH, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol. 2015;45(3):854–64. doi:10.1002/eji.201445127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201445127</ArticleId>
            <ArticleId IdType="pubmed">25487143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park H-Y, Tan PS, Kavishna R, Ker A, Lu J, Chan CEZ, Hanson BJ, MacAry PA, Caminschi I, Shortman K, et al. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells. NPJ Vaccines. 2017;2(1):31. doi:10.1038/s41541-017-0033-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41541-017-0033-5</ArticleId>
            <ArticleId IdType="pmc">PMC5674066</ArticleId>
            <ArticleId IdType="pubmed">29263886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez-Ruiz D, Ng WY, Holz LE, Ma JZ, Zaid A, Wong YC, Lau LS, Mollard V, Cozijnsen A, Collins N, et al. Liver-resident memory CD8 + T cells form a front-line defense against malaria liver-stage infection. Immunity. 2016;45(4):889–902. doi:10.1016/j.immuni.2016.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.08.011</ArticleId>
            <ArticleId IdType="pubmed">27692609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato Y, Steiner TM, Park H-Y, Hitchcock RO, Zaid A, Hor JL, Devi S, Davey GM, Vremec D, Tullett KM, et al. Display of native antigen on cDC1 that have spatial access to both T and B cells underlies efficient humoral vaccination. J Immunol. 2020;205(7):1842–56. doi:10.4049/jimmunol.2000549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.2000549</ArticleId>
            <ArticleId IdType="pmc">PMC7504891</ArticleId>
            <ArticleId IdType="pubmed">32839238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood. 2012;119(10):2284–92. doi:10.1182/blood-2011-08-373944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-08-373944</ArticleId>
            <ArticleId IdType="pubmed">22234694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tullett KM, Leal Rojas IM, Minoda Y, Tan PS, Zhang J-G, Smith C, Khanna R, Shortman K, Caminschi I, Lahoud MH, et al. Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition. JCI Insight. 2016;1(7):e87102. doi:10.1172/jci.insight.87102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.87102</ArticleId>
            <ArticleId IdType="pmc">PMC5033826</ArticleId>
            <ArticleId IdType="pubmed">27699265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearson FE, Tullett KM, Leal‐Rojas IM, Haigh OL, Masterman K-A, Walpole C, Bridgeman JS, McLaren JE, Ladell K, Miners K, et al. Human CLEC9A antibodies deliver Wilms’ tumor 1 (WT1) antigen to CD141 + dendritic cells to activate naïve and memory WT1-specific CD8 + T cells. Clin Transl Immunol. 2020;9(6):e1141. doi:10.1002/cti2.1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cti2.1141</ArticleId>
            <ArticleId IdType="pmc">PMC7292901</ArticleId>
            <ArticleId IdType="pubmed">32547743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masterman KA, Haigh OL, Tullett KM, Leal-Rojas IM, Walpole C, Pearson FE, Cebon J, Schmidt C, O’Brien L, Rosendahl N, et al. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naive and memory NY-ESO-1-specific CD8(+) T cells. J Immunother Cancer. 2020;8(2):e000691. doi:10.1136/jitc-2020-000691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-000691</ArticleId>
            <ArticleId IdType="pmc">PMC7394304</ArticleId>
            <ArticleId IdType="pubmed">32737142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A. 2011;108(6):2384–89. doi:10.1073/pnas.1019547108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1019547108</ArticleId>
            <ArticleId IdType="pmc">PMC3038758</ArticleId>
            <ArticleId IdType="pubmed">21262813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fossum E, Tesfaye DY, Bobic S, Gudjonsson A, Braathen R, Lahoud MH, Caminschi I, Bogen B. Targeting antigens to different receptors on conventional type 1 dendritic cells impacts the immune response. J Immunol. 2020;205(3):661–73. doi:10.4049/jimmunol.1901119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1901119</ArticleId>
            <ArticleId IdType="pubmed">32591401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008;20(2):211–20. doi:10.1016/j.coi.2008.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2008.04.009</ArticleId>
            <ArticleId IdType="pubmed">18502632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching PA, Campone M, Bachelot T, Krivorotko P, Chan S, et al. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Res Treat. 2017;162(3):479–88. doi:10.1007/s10549-017-4130-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-017-4130-y</ArticleId>
            <ArticleId IdType="pmc">PMC5332485</ArticleId>
            <ArticleId IdType="pubmed">28176175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, et al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: A phase II randomized study. Cancer Immunol Res. 2018;6(3):320–31. doi:10.1158/2326-6066.CIR-17-0386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-17-0386</ArticleId>
            <ArticleId IdType="pubmed">29358173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, et al. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 2019;68(2):331–40. doi:10.1007/s00262-018-2274-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-018-2274-1</ArticleId>
            <ArticleId IdType="pmc">PMC6394509</ArticleId>
            <ArticleId IdType="pubmed">30430205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713–21. doi:10.1182/blood-2017-04-780155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-04-780155</ArticleId>
            <ArticleId IdType="pmc">PMC5649080</ArticleId>
            <ArticleId IdType="pubmed">28830889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947. doi:10.3389/fimmu.2018.00947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00947</ArticleId>
            <ArticleId IdType="pmc">PMC5941317</ArticleId>
            <ArticleId IdType="pubmed">29770138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet J-P, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208(12):2357–66. doi:10.1084/jem.20111171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20111171</ArticleId>
            <ArticleId IdType="pmc">PMC3256967</ArticleId>
            <ArticleId IdType="pubmed">22065672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207(6):1247–60. doi:10.1084/jem.20092140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20092140</ArticleId>
            <ArticleId IdType="pmc">PMC2882828</ArticleId>
            <ArticleId IdType="pubmed">20479116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubert M, Gobbini E, Couillault C, Manh TPV, Doffin A-C, Berthet J, Rodriguez C, Ollion V, Kielbassa J, Sajous C, et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci Immunol. 2020;5(46):eaav3942. doi:10.1126/sciimmunol.aav3942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aav3942</ArticleId>
            <ArticleId IdType="pubmed">32303573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy. 2016;8(8):877–88. doi:10.2217/imt-2015-0021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2015-0021</ArticleId>
            <ArticleId IdType="pmc">PMC5619162</ArticleId>
            <ArticleId IdType="pubmed">27381684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003. doi:10.1084/jem.20101158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20101158</ArticleId>
            <ArticleId IdType="pmc">PMC3182061</ArticleId>
            <ArticleId IdType="pubmed">21930769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. 2011;208(10):2005–16. doi:10.1084/jem.20101159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20101159</ArticleId>
            <ArticleId IdType="pmc">PMC3182064</ArticleId>
            <ArticleId IdType="pubmed">21930765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206(7):1589–602. doi:10.1084/jem.20090247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20090247</ArticleId>
            <ArticleId IdType="pmc">PMC2715098</ArticleId>
            <ArticleId IdType="pubmed">19564349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y, et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Cancer Res. 2018;78(2):463–74. doi:10.1158/0008-5472.CAN-17-1980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-1980</ArticleId>
            <ArticleId IdType="pubmed">29187401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, Pring J, Pack M, Buckley N, Matei I, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50(7):924–30. doi:10.1038/bmt.2015.74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2015.74</ArticleId>
            <ArticleId IdType="pmc">PMC4532305</ArticleId>
            <ArticleId IdType="pubmed">25915810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavoni G, Gabriele L, Mattei F. The dual role of IRF8 in cancer immunosurveillance. Oncoimmunology. 2013;2(8):e25476. doi:10.4161/onci.25476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/onci.25476</ArticleId>
            <ArticleId IdType="pmc">PMC3810266</ArticleId>
            <ArticleId IdType="pubmed">24175153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Zhou YJ, Ma W, Zhang W, Aljoufi A, Luh T, Lucero K, Liang D, Thomsen M, Bhagat G, et al. Lineage specification of human dendritic cells is marked by IRF8 expression in hematopoietic stem cells and multipotent progenitors. Nat Immunol. 2017;18(8):877–88. doi:10.1038/ni.3789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3789</ArticleId>
            <ArticleId IdType="pmc">PMC5743223</ArticleId>
            <ArticleId IdType="pubmed">28650480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393(6684):474–78. doi:10.1038/30989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/30989</ArticleId>
            <ArticleId IdType="pubmed">9624003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393(6684):478–80. doi:10.1038/30996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/30996</ArticleId>
            <ArticleId IdType="pubmed">9624004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, Garbi N, Kaisho T, Germain RN, Kastenmuller W. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell. 2015;162(6):1322–37. doi:10.1016/j.cell.2015.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.08.004</ArticleId>
            <ArticleId IdType="pmc">PMC4567961</ArticleId>
            <ArticleId IdType="pubmed">26296422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hor JL, Whitney PG, Zaid A, Brooks AG, Heath WR, Mueller SN. Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4+ and CD8+ T cell activation to localized viral infection. Immunity. 2015;43(3):554–65. doi:10.1016/j.immuni.2015.07.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.07.020</ArticleId>
            <ArticleId IdType="pubmed">26297566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT, Bagadia P, Liu T, Briseno CG, et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature. 2020;584(7822):624–29. doi:10.1038/s41586-020-2611-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2611-3</ArticleId>
            <ArticleId IdType="pmc">PMC7469755</ArticleId>
            <ArticleId IdType="pubmed">32788723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashour D, Arampatzi P, Pavlovic V, Forstner KU, Kaisho T, Beilhack A, Erhard F, Lutz MB. IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction. JCI Insight. 2020;5(10). doi:10.1172/jci.insight.135143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.135143</ArticleId>
            <ArticleId IdType="pmc">PMC7259537</ArticleId>
            <ArticleId IdType="pubmed">32434994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alcantara-Hernandez M, Leylek R, Wagar LE, Engleman EG, Keler T, Marinkovich MP, Davis MM, Nolan GP, Idoyaga J. High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization. Immunity. 2017. 
e6;47(6):1037–50. doi:10.1016/j.immuni.2017.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC5738280</ArticleId>
            <ArticleId IdType="pubmed">29221729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botting RA, Bertram KM, Baharlou H, Sandgren KJ, Fletcher J, Rhodes JW, Rana H, Plasto TM, Wang XM, Lim JJK, et al. Phenotypic and functional consequences of different isolation protocols on skin mononuclear phagocytes. J Leukoc Biol. 2017;101(6):1393–403. doi:10.1189/jlb.4A1116-496R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.4A1116-496R</ArticleId>
            <ArticleId IdType="pmc">PMC5433859</ArticleId>
            <ArticleId IdType="pubmed">28270408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;8(11):e1638212. doi:10.1080/2162402X.2019.1638212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2019.1638212</ArticleId>
            <ArticleId IdType="pmc">PMC6791419</ArticleId>
            <ArticleId IdType="pubmed">31646087</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
